Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT06298630

Long-term Follow-up Study of BRL-101 for TDT

Conditions: Thalassemia, Beta

Sex: All

Ages: 3 Years – 35 Years

Healthy volunteers: No

Enrollment: 45

Sponsor: Bioray Laboratories

Location: Nanfang Hospital, Southern Medical University Guangzhou Guangdong

Summary

Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.

Eligibility Criteria

Inclusion Criteria: 1. Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s) 2. Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia. Exclusion Criteria: \- There are no exclusion criteria for this study

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06298630). StuddyBuddy aggregates publicly available trial information.